Compare IDEXX Laboratories, Inc. (IDXX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.7× Norwegian Cruise Line Holdings Ltd's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 22,683,268). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| IDXX | NCLH | |
|---|---|---|
Market Cap | $40.43B | $7.11B |
Volume | 692,164 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $25.02 |
52-Week Low | $504.70 | $14.12 |
Typical Hold Time | 46 Days | 68 Days |
Enterprise Value | $41.32B | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% with bullish technical signals and strong earnings beats. The company shows improving fundamentals with $9.83B revenue in 2025 and net income of $423M, while maintaining attractive valuation metrics including a 9.39 P/E ratio. Recent news highlights management's expectation for Q3 2026 results to exceed guidance, driven by better-than-expected revenue performance.
NCLH presents a compelling investment case with analyst consensus pointing to 35% upside to the $20.86 price target. However, investors face risks from persistent yield pressure, high debt levels ($11.78B long-term debt), and competitive Caribbean pricing. The stock's outlook remains positive given consecutive earnings beats and management's pricing strategies to stabilize performance through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
